Kathy serves as President and Chief Executive Officer of Electra Therapeutics. She brings broad experience in corporate development, portfolio management, technical operations, and product commercialization. Previously, she was Chief Operating Officer of Star Therapeutics, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage into the clinic. Prior to joining Star, Kathy served as Vice President of Commercial Development at True North Therapeutics, where she played a key role in assessing opportunities and shaping the value proposition for its portfolio. Following True North’s acquisition by Bioverativ/Sanofi, she advanced numerous programs through preclinical and clinical development as Head of New Product Planning for the complement franchise. Kathy spent nine years of her career at Gilead Sciences, where she led the launch and market development of numerous products in hepatitis B and hepatitis C, including SOVALDI and HARVONI, two of the most successful launches in biopharmaceutical history. She also currently serves as an independent director on the board of Neuron23. Kathy earned her PharmD and MBA at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.